Author

Amy Barton Pai

Observed names: A B Pai, A PAI, Amy Barton Alston, Amy Barton PAI, Amy Pai

Observed institutions: Brigham and Women's Hospital, Boston Children's Hospital, National Institutes of Health, University of Minnesota, The University of Texas MD Anderson Cancer Center, University of New Mexico, University of Michigan, American Society of Nephrology, Albany College of Pharmacy and Health Sciences, Vifor Pharma (Switzerland), Delray Medical Center, University of New Mexico Health Sciences Center, Albany Medical College, Dialysis Clinic, Inc., Columbia University

ORCID: 0000-0002-7131-5267

Observed ORCID: 0000-0002-7131-5267

OpenAlex ID: A5047374751

Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

2016 · Iain C. Macdougall, Andreas J. Bircher, et al. · Kidney International · 492

PDF

Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

2021 · Jodie L. Babitt, Michele F. Eisenga, et al. · Kidney International · 235

PDF

Symptom Prioritization among Adults Receiving In-Center Hemodialysis: A Mixed Methods Study

2018 · Jennifer E. Flythe, Tandrea Hilliard, et al. · Clinical Journal of the American Society of Nephrology · 176

Estimation of creatinine clearance in morbidly obese patients

2009 · Jasmina A. Demirovic, Amy Barton Pai, et al. · American Journal of Health-System Pharmacy · 170

Reduced Drug Use and Hospitalization Rates in Patients Undergoing Hemodialysis Who Received Pharmaceutical Care: A 2‐Year, Randomized, Controlled Study

2009 · Amy Barton Pai, Alex Boyd, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 116

Fostering Innovation in Symptom Management among Hemodialysis Patients: Paths Forward for Insomnia, Muscle Cramps, and Fatigue

2018 · Jennifer E. Flythe, Tandrea Hilliard, et al. · Clinical Journal of the American Society of Nephrology · 107

Medication-related Problems in CKD

2010 · Katie E. Cardone, Shaffeeulah Bacchus, et al. · Advances in Chronic Kidney Disease · 95

PDF

Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis

2014 · David M. Charytan, Amy Barton Pai, et al. · Journal of the American Society of Nephrology · 85

Medication Reconciliation and Therapy Management in Dialysis-Dependent Patients: Need for a Systematic Approach

2013 · Amy Barton Pai, Katie E. Cardone, et al. · Clinical Journal of the American Society of Nephrology · 80

Comparison of Oxidative Stress Markers After Intravenous Administration of Iron Dextran, Sodium Ferric Gluconate, and Iron Sucrose in Patients Undergoing Hemodialysis

2007 · Amy Barton Pai, Alex V. Boyd, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 74

Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm

2004 · Amy Barton Pai, Manjunath P. Pai · American Journal of Health-System Pharmacy · 51

Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?

2012 · Amy Barton Pai, Garba · Journal of Blood Medicine · 49

PDF

2009 · Amy Barton PAI, Alex BOYD, et al. · Hemodialysis International · 49

Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose

2011 · Amy Barton Pai, Todd Conner, et al. · BioMetals · 46

How to select a nanosimilar

2017 · Alain Astier, Amy Barton Pai, et al. · Annals of the New York Academy of Sciences · 45

PDF

Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival

2010 · Ajay Gupta, Jiaying Zhuo, et al. · BMC Nephrology · 44

PDF

Non-Transferrin-Bound Iron Is Associated with Enhanced Staphylococcus aureus Growth in Hemodialysis Patients Receiving Intravenous Iron Sucrose

2006 · Amy Barton Pai, Manjunath P. Pai, et al. · American Journal of Nephrology · 40

Plasma Pharmacokinetics of Two Consecutive Doses of Ferumoxytol in Healthy Subjects

2010 · A B Pai, J C Nielsen, et al. · Clinical Pharmacology & Therapeutics · 35

Lipoteichoic Acid from Staphylococcus aureus Induces Lung Endothelial Cell Barrier Dysfunction: Role of Reactive Oxygen and Nitrogen Species

2012 · Amy Barton Pai, Heena Patel, et al. · PLoS ONE · 27

PDF

Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation

2017 · Amy Barton Pai · Annals of the New York Academy of Sciences · 26

PDF

NSAID-avoidance education in community pharmacies for patients at high risk for acute kidney injury, upstate New York, 2011.

2014 · Soo Min Jang, Jennifer Cerulli, et al. · PubMed Central · 26

PDF

Elevated serum creatinine levels associated with fenofibrate therapy

2008 · Charles R. McQuade, Jennifer Griego, et al. · American Journal of Health-System Pharmacy · 25

Keeping kidneys safe: The pharmacist's role in NSAID avoidance in high-risk patients

2014 · Amy Barton Pai · Journal of the American Pharmacists Association · 23

Drug Transporter Function—Implications in CKD

2016 · Michael H. Schwenk, Amy Barton Pai · Advances in Chronic Kidney Disease · 22

Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?

2020 · Ernane Souza, Katherine H. Cho, et al. · Expert Opinion on Investigational Drugs · 21

Works count: 70

Citation count: 2,422

H-index: 23

I10-index: 37